PATENT CLAIM ANALYSIS

Application Number: 16059121
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-07
Patent Classification: ["514", "04400A"]

Abstract:
The invention relates to isolated nucleic acids and rAAV-based compositions, methods and kits useful for treating genetic diseases (e.g., alpha-1 antitrypsin deficiency).

Claim (Index 5):
The isolated nucleic acid of  claim 4 , further comprising a third region encoding a one or more second miRNAs comprising a nucleic acid having sufficient sequence complementary to hybridize with and inhibit expression of the endogenous mRNA, wherein the third region is positioned within an untranslated portion of the second region.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 96.0
- Lexical Diversity: 1.08
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14113118', '15098833', '13642719', '14445670', '15705909']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7546296537779562
- 35 USC 102 Novelty (BERT): 0.7044900371012675
- Combined Prediction Score: 0.7496156921102873
- Mean Citation Score: 539.9870999999998
- Max Citation Score: 791.0799599999997
- Similarity Product: 709.8300165699291

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test